In the meta- analysis , tadalafil and sildenafil appeared to have similar efficacies and overall adverse event rates .
However , compared with sildenafil , tadalafil significantly improved psychological outcomes .
Furthermore , the patients and their partners preferred tadalafil over sildenafil , and no significant difference was found in the adherence and persistence rates between tadalafil and sildenafil .
Additionally , the myalgia and back pain rates were higher and the flushing rate was lower with tadalafil than with sildenafil .
Conclusion Tadalafil shares a similar efficacy and safety with sildenafil and significantly improves patients ’ sexual confidence .
Furthermore , patients and their partners prefer tadalafil to sildenafil .
Hence , tadalafil may be a better choice for ED treatment
Aims Erectile dysfunction ( ED ) is a major care problem worldwide .
Tadalafil and sildenafil are the two most common phosphodiesterase 5 inhibitors used to treat ED .
This systematic review and meta- analysis were conducted to directly compare tadalafil with sildenafil for the treatment of ED .
Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.
INTRODUCTION Several preference studies comparing a short-acting with a longer-acting phosphodiesterase type 5 inhibitor have been conducted in men . Most men in those studies preferred tadalafil rather than sildenafil , and recent post hoc analysis of one study described several factors associated with men 's treatment preference . No prospect i ve studies have investigated the woman partners ' preferences . AIM To investigate the treatment preference of women who were partners of men using oral medications for erectile dysfunction ( ED ) in a single-center open-label crossover study . METHODS One hundred heterosexual couples in stable relationships , with male partners having ED based on the erectile function subscale of the International Index of Erectile Function , were r and omly assigned to receive sildenafil or tadalafil for a 12-week phase , followed by another 12-week period using the alternate drug . Male and female participants completed sexual event diaries during both study phases , and the female participants were interviewed at baseline , midpoint , and end of study . MAIN OUTCOME MEASURES Primary outcome data were the women 's final interviews during which they were asked which drug they preferred and their reasons for that preference . RESULTS A total of 79.2 % of the women preferred their partners ' use of tadalafil , while 15.6 % preferred sildenafil . Preference was not affected by age or treatment order r and omization . Women preferring tadalafil reported feeling more relaxed , experiencing less pressure , and enjoying a more natural or spontaneous sexual experience as reasons for their choice . Mean number of tablets used , events recorded , events per week , and days between events were not significantly different during each study phase . CONCLUSION Women 's preferences were similar to men when using these two drugs . While the women 's reasons for preferring tadalafil emphasized relaxed , satisfying , longer-lasting sexual experiences , those preferring sildenafil focused on satisfaction and drug effectiveness for their partner
In the meta- analysis , tadalafil and sildenafil appeared to have similar efficacies and overall adverse event rates .
However , compared with sildenafil , tadalafil significantly improved psychological outcomes .
Furthermore , the patients and their partners preferred tadalafil over sildenafil , and no significant difference was found in the adherence and persistence rates between tadalafil and sildenafil .
Additionally , the myalgia and back pain rates were higher and the flushing rate was lower with tadalafil than with sildenafil .
Conclusion Tadalafil shares a similar efficacy and safety with sildenafil and significantly improves patients ’ sexual confidence .
Furthermore , patients and their partners prefer tadalafil to sildenafil .
Hence , tadalafil may be a better choice for ED treatment
Aims Erectile dysfunction ( ED ) is a major care problem worldwide .
Tadalafil and sildenafil are the two most common phosphodiesterase 5 inhibitors used to treat ED .
This systematic review and meta- analysis were conducted to directly compare tadalafil with sildenafil for the treatment of ED .